Literature DB >> 23843182

Patients with chronic kidney disease/diabetes mellitus: the high-risk profile in acute coronary syndrome.

Usman Baber1, Uschi Auguste.   

Abstract

Chronic kidney disease (CKD) and diabetes mellitus (DM) are highly prevalent, morbid diseases that are very common among patients presenting with acute coronary syndromes (ACS). Despite significant reductions in cardiovascular morbidity and mortality over the last half century, residual vascular risk remains disproportionately high in these populations. In large part, this is attributable to pre-existing vascular morbidity and substantial enrichment of traditional risk factors among those with either CKD or DM. Other factors, such as less aggressive therapeutic intervention and a unique atherothrombotic phenotype, are also contributory. The introduction of novel antiplatelet and antithrombotic agents over the last several years provides fresh opportunities to improve the adverse prognosis among patients with CKD or DM and concomitant ACS.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23843182     DOI: 10.1007/s11886-013-0386-y

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  69 in total

1.  Impact of diabetes mellitus on the safety and effectiveness of bivalirudin in patients with acute myocardial infarction undergoing primary angioplasty: analysis from the HORIZONS-AMI (Harmonizing Outcomes with RevasculariZatiON and Stents in Acute Myocardial Infarction) trial.

Authors:  Bernhard Witzenbichler; Roxana Mehran; Giulio Guagliumi; Dariusz Dudek; Kurt Huber; Ran Kornowski; Thomas D Stuckey; Martin Fahy; Helen Parise; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2011-07       Impact factor: 11.195

2.  C-reactive protein and glycemic control in adults with diabetes.

Authors:  Dana E King; Arch G Mainous; Thomas A Buchanan; William S Pearson
Journal:  Diabetes Care       Date:  2003-05       Impact factor: 19.112

3.  Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Jack Hirsh; Robert Raschke
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

4.  Pathology of acute myocardial infarction with particular reference to occlusive coronary thrombi.

Authors:  M J Davies; N Woolf; W B Robertson
Journal:  Br Heart J       Date:  1976-07

5.  Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: an ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) substudy.

Authors:  Roxana Mehran; Eugenia Nikolsky; Alexandra J Lansky; Ajay J Kirtane; Young-Hak Kim; Frederick Feit; Steven Manoukian; Jeffrey W Moses; Ramin Ebrahimi; E Magnus Ohman; Harvey D White; Stuart J Pocock; George D Dangas; Gregg W Stone
Journal:  JACC Cardiovasc Interv       Date:  2009-08       Impact factor: 11.195

6.  Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes.

Authors:  Jin H Han; Abhinav Chandra; Jyotsna Mulgund; Matthew T Roe; Eric D Peterson; Lynda A Szczech; Uptal Patel; E Magnus Ohman; Christopher J Lindsell; W Brian Gibler
Journal:  Am J Med       Date:  2006-03       Impact factor: 4.965

7.  Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study.

Authors:  A K Gitt; R Schiele; H Wienbergen; U Zeymer; S Schneider; M G Gottwik; J Senges
Journal:  Acta Diabetol       Date:  2003-12       Impact factor: 4.280

8.  Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38.

Authors:  Stephen D Wiviott; Eugene Braunwald; Dominick J Angiolillo; Simha Meisel; Anthony J Dalby; Freek W A Verheugt; Shaun G Goodman; Ramon Corbalan; Drew A Purdy; Sabina A Murphy; Carolyn H McCabe; Elliott M Antman
Journal:  Circulation       Date:  2008-08-31       Impact factor: 29.690

9.  Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Authors:  Stefan James; Dominick J Angiolillo; Jan H Cornel; David Erlinge; Steen Husted; Frederic Kontny; Juan Maya; Josë C Nicolau; Jindrich Spinar; Robert F Storey; Susanna R Stevens; Lars Wallentin
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

10.  Full accounting of diabetes and pre-diabetes in the U.S. population in 1988-1994 and 2005-2006.

Authors:  Catherine C Cowie; Keith F Rust; Earl S Ford; Mark S Eberhardt; Danita D Byrd-Holt; Chaoyang Li; Desmond E Williams; Edward W Gregg; Kathleen E Bainbridge; Sharon H Saydah; Linda S Geiss
Journal:  Diabetes Care       Date:  2008-11-18       Impact factor: 17.152

View more
  3 in total

1.  Decade-long trends (1999-2009) in the characteristics, management, and hospital outcomes of patients hospitalized with acute myocardial infarction with prior diabetes and chronic kidney disease.

Authors:  Mayra Tisminetzky; David D McManus; Alon Dor; Ruben Miozzo; Jorge Yarzebski; Joel M Gore; Robert J Goldberg
Journal:  Int J Nephrol Renovasc Dis       Date:  2015-05-05

2.  Physical, cognitive and emotional factors contributing to quality of life, functional health and participation in community dwelling in chronic kidney disease.

Authors:  Ulla K Seidel; Janine Gronewold; Michaela Volsek; Olga Todica; Andreas Kribben; Heike Bruck; Dirk M Hermann
Journal:  PLoS One       Date:  2014-03-10       Impact factor: 3.240

3.  Risk for recurrent cardiovascular disease events among patients with diabetes and chronic kidney disease.

Authors:  Demetria Hubbard; Lisandro D Colantonio; Robert S Rosenson; Todd M Brown; Elizabeth A Jackson; Lei Huang; Kate K Orroth; Stephanie Reading; Mark Woodward; Vera Bittner; Orlando M Gutierrez; Monika M Safford; Michael E Farkouh; Paul Muntner
Journal:  Cardiovasc Diabetol       Date:  2021-03-01       Impact factor: 9.951

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.